ADMA Biologics, Inc.
$10.88
▲
0.88%
2026-04-21 05:05:00
www.admabiologics.com
NGM: ADMA
Explore ADMA Biologics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.6 B
Current Price
$10.88
52W High / Low
$25.67 / $7.21
Stock P/E
17.68
Book Value
$2.01
Dividend Yield
—
ROCE
34.51%
ROE
35.56%
Face Value
—
EPS
$0.6
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
640
Beta
0.82
Debt / Equity
110.67
Current Ratio
6.71
Quick Ratio
3.74
Forward P/E
7.03
Price / Sales
4.53
Enterprise Value
$44.06 B
EV / EBITDA
220.8
EV / Revenue
86.36
Rating
Buy
Target Price
$23.5
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LENZ Therapeutics, Inc. | $10.13 | — | $319.19 M | — | -32.01% | -33.63% | $50.4 / $8.25 | $9.07 |
| 2. | uniQure N.V. | $18.04 | — | $1.07 B | — | -24.65% | -2.07% | $71.5 / $8.73 | $3.19 |
| 3. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
| 4. | Gyre Therapeutics, Inc. | $7.94 | 144.23 | $725.03 M | — | 7.77% | 8.21% | $11.78 / $6.57 | $1.16 |
| 5. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 6. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 7. | Jade Biosciences, Inc. | $23.5 | — | $1.13 B | 0% | -34.07% | -89.19% | $100.1 / $6.57 | $6.74 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 139.16 M | 134.22 M | 121.98 M | 114.8 M | 117.55 M |
| Operating Profit | 62.75 M | 51.01 M | 42.8 M | 34.88 M | 38.32 M |
| Net Profit | 49.38 M | 36.43 M | 34.22 M | 26.9 M | 111.9 M |
| EPS in Rs | 0.21 | 0.15 | 0.14 | 0.11 | 0.47 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 510.17 M | 426.45 M | 258.21 M | 154.08 M |
| Operating Profit | 191.44 M | 138.98 M | 21.63 M | -39.37 M |
| Net Profit | 146.93 M | 197.67 M | -28.24 M | -65.9 M |
| EPS in Rs | 0.62 | 0.83 | -0.12 | -0.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 624.24 M | 488.68 M | 329.18 M | 348.46 M |
| Total Liabilities | 146.92 M | 139.66 M | 193.98 M | 196.49 M |
| Equity | 477.32 M | 349.02 M | 135.21 M | 151.97 M |
| Current Assets | 466.51 M | 331.41 M | 257.01 M | 270.4 M |
| Current Liabilities | 69.54 M | 55.54 M | 49.81 M | 39.27 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 50.4 M | 118.67 M | 8.8 M | -59.51 M |
| Investing CF | -21.89 M | -8.57 M | -4.98 M | -13.91 M |
| Financing CF | -44.02 M | -58.3 M | -38.99 M | 108.85 M |
| Free CF | 27.5 M | 110.1 M | 3.82 M | -73.42 M |
| Capex | -22.89 M | -8.57 M | -4.98 M | -13.91 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 65.15% | 67.59% | — | — |
| Earnings Growth % | 800% | 57.15% | — | — |
| Profit Margin % | 46.35% | -10.94% | -42.77% | — |
| Operating Margin % | 32.59% | 8.38% | -25.55% | — |
| Gross Margin % | 51.48% | 34.44% | 22.89% | — |
| EBITDA Margin % | 34.63% | 1.98% | -25.64% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.